scispace - formally typeset
H

Hong Zhao

Researcher at Peking University

Publications -  31
Citations -  1743

Hong Zhao is an academic researcher from Peking University. The author has contributed to research in topics: Liver biopsy & HBeAg. The author has an hindex of 7, co-authored 31 publications receiving 1243 citations. Previous affiliations of Hong Zhao include Zhejiang University.

Papers
More filters
Journal ArticleDOI

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

TL;DR: Tocilizumab is a blocker of IL-6R, which can effectively block IL- 6 signal transduction pathway, and is likely to become an effective drug for patients with severe COVID-19.
Journal ArticleDOI

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.

TL;DR: Tocilizumab combined with or without favipiravir can effectively improve the pulmonary inflammation of COVID-19 patients and inhibit the deterioration of the disease.
Journal ArticleDOI

Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.

TL;DR: The possible mechanism of pulmonary fibrosis caused by SARS‐CoV‐2 is proposed, and the therapeutic value of two drugs (pirfenidone and nintedanib) for idiopathic pulmonary Fibrosis in COVID‐19‐induced pulmonary fibrot is suggested.
Journal ArticleDOI

Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients.

TL;DR: The 30 existing noninvasive models were not suitable for assessing each stage of fibrosis except cirrhosis before and after antiviral therapy, especially in gauging progression and regression of liver fibrosis following therapy.